Pfizer's new corona vaccine is effective 6 months after administration, even for mutant strains in South Africa
Six months after the second dose of the new coronavirus infection (COVID-19) vaccine '
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study | pfpfizeruscom
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious
Pfizer's COVID-19 vaccine effective after 6 months and works against problem variant | Live Science
https://www.livescience.com/pfizer-vaccine-effective-six-months.html
A study in which Pfizer and BioNTech followed more than 46,000 people who participated in a Phase III clinical trial of BNT162b2 confirmed a total of 927 cases of COVID-19 within 6 months of receiving the vaccine or placebo. I did. Of these, 850 were confirmed in the control group that received the placebo, and only 77 cases occurred in the experimental group that received the vaccine, and the effectiveness of the vaccine was 91.3%. Pfizer says.
Of the COVID-19 cases identified in the study, 32 were defined by the Centers for Disease Control and Prevention (CDC) as 'severe COVID-19 cases,' all of which were placebo-treated controls. It was confirmed in the group, and those who received the vaccine did not show severe symptoms. In addition, the effectiveness of the vaccine was generally consistent regardless of demographics such as age, gender, and race, and various underlying diseases.
The analysis also included 800 people living in South Africa, where more infectious mutants are endemic, but no cases of people in the experimental group developing COVID-19 were identified. Although the number of 800 is not large enough, it has been suggested that 'BNT162b2' may be effective against mutant strains in South Africa. In addition, the number of COVID-19 cases confirmed in the control group was 9, and 6 of them were due to mutant strains in South Africa.
Pfizer has followed more than 44,000 vaccinated subjects for safety, with at least 12,000 being followed for 6 months from the second dose and still presenting serious problems. I also report that there is no such thing. 'The high efficacy observed against South African mutants for up to 6 months after the second vaccination is the overall efficacy of the vaccine,' said Albert Bourla, chairman and CEO of Pfizer. We will provide more trust to you. '
At the time of writing, BNT162b2 was approved for people over the age of 16, but Pfizer and BioNTech are also conducting clinical trials in children. According to Pfizer's announcement, clinical trials of 2,260 children aged 12 to 15 years in the United States have confirmed 100% efficacy and safety.
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents | pfpfizeruscom
Pfizer says Covid vaccine 100 percent effective in children ages 12 to 15
https://www.nbcnews.com/health/health-news/pfizer-says-its-covid-vaccine-100-percent-effective-young-teens-n1262550
In an experiment with children aged 12 to 15 years, about half received the COVID-19 vaccine and the other half received the placebo. In subsequent follow-up, 18 of the subjects developed COVID-19, all of whom were placebo-treated controls. In addition, it was found that the vaccinated subjects produced sufficient neutralizing antibodies to fight the virus, similar to adults 16 years and older.
'We see an urgent need to increase approval for vaccine use for the younger generation, and we are encouraged by clinical trial data for adolescents aged 12 to 15 years,' said Bula. Within a few weeks, we will submit an amendment to the Emergency Use Authorization to the US Food and Drug Administration (FDA) and other regulators around the world, which will vaccinate this age group before the start of the next year. I want to get started. '
In addition, Pfizer and BioNTech announced that they started clinical trials of 'BNT162b2' in children aged 5 to 11 years in late March 2021. A clinical trial will be started in April for infants aged 2 to 5 years to evaluate the efficacy and safety of the vaccine.
Related Posts:
in Science, Posted by log1h_ik